David J. Chang
Chief Medical OfficerDr. David J. Chang, M.D., M.P.H., FACR serves as Chief Medical Officer of Cabaletta Bio, Inc. since June 2019. Dr. Chang joined the Cabaletta Bio, Inc. in June 2019. From June 2015 to May 2019, he was Senior Vice President and Head, Inflammation, Autoimmunity & Neuroscience, or IA&NS, Global Medicines Development at AstraZeneca Pharmaceuticals LP, where he oversaw development projects of both biologics and small molecules in a variety of indications and led the late-stage clinical development organization for IA&NS. Dr. Chang has experience in autoimmunity, neuroscience and inflammatory diseases at both biopharmaceutical companies and in academia. Earlier in his career, he held clinical leadership roles at Merck and Wyeth. Dr. Chang also was recently Co-chair of the Foundation of the NIH Biomarkers Consortium Inflammation From October 2007 to June 2015, Dr. Chang served in various positions at GlaxoSmithKline plc, including VP and Head, Immuno-Inflammation, Clinical Development. Dr. Chang is an adjunct associate professor in the Division of Rheumatology at the Perelman School of Medicine of the University of Pennsylvania. He received his M.D. from New York University School of Medicine, his M.P.H. from Emory University and his B.S. from Yale University. Dr. Chang completed his internship and residency in internal medicine at the New York Hospital—Cornell University Medical Center and fellowship in rheumatology at the Hospital for Special Surgery—Cornell University Medical Center.
Positions
- Company NameCabaletta Bio, Inc.Stock CodeCABAPositionChief Medical OfficerColleagues
- SASteven A. NichtbergerCo-Founder, Chairman, CEO & President
- GKGwendolyn K. BinderPresident of Science & Technology
- MCMichael C. MiloneCo-Founder & Co-Chair of Scientific Advisory Board
- APAimee PayneCo-Founder & Co-Chair of Scientific Advisory Board
- RCRichard C. HenriquesIndependent Director
- SCScott C. BrunIndependent Director
